Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATAI NASDAQ:CCCC NASDAQ:GLUE NYSE:NUVB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATAIAtai Beckley$4.96-4.4%$4.32$2.53▼$6.75$1.91B1.568.72 million shs11.54 million shsCCCCC4 Therapeutics$4.14-3.7%$3.70$1.44▼$5.17$475.44M2.93.43 million shs1.90 million shsGLUEMonte Rosa Therapeutics$23.25-4.0%$19.43$4.12▼$25.77$2.05B1.561.60 million shs996,079 shsNUVBNuvation Bio$5.58-2.1%$5.01$2.03▼$9.75$1.98B1.528.21 million shs5.50 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATAIAtai Beckley-4.43%-7.46%+25.57%+30.87%+78.74%CCCCC4 Therapeutics-3.72%-4.83%+7.53%+51.09%+177.85%GLUEMonte Rosa Therapeutics-3.97%-2.72%+42.03%+35.81%+360.85%NUVBNuvation Bio-1.81%-0.23%+15.93%+24.49%+167.72%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATAIAtai Beckley$4.96-4.4%$4.32$2.53▼$6.75$1.91B1.568.72 million shs11.54 million shsCCCCC4 Therapeutics$4.14-3.7%$3.70$1.44▼$5.17$475.44M2.93.43 million shs1.90 million shsGLUEMonte Rosa Therapeutics$23.25-4.0%$19.43$4.12▼$25.77$2.05B1.561.60 million shs996,079 shsNUVBNuvation Bio$5.58-2.1%$5.01$2.03▼$9.75$1.98B1.528.21 million shs5.50 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATAIAtai Beckley-4.43%-7.46%+25.57%+30.87%+78.74%CCCCC4 Therapeutics-3.72%-4.83%+7.53%+51.09%+177.85%GLUEMonte Rosa Therapeutics-3.97%-2.72%+42.03%+35.81%+360.85%NUVBNuvation Bio-1.81%-0.23%+15.93%+24.49%+167.72%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATAIAtai Beckley 2.92Moderate Buy$15.25207.46% UpsideCCCCC4 Therapeutics 2.57Moderate Buy$7.7587.20% UpsideGLUEMonte Rosa Therapeutics 2.67Moderate Buy$33.3343.37% UpsideNUVBNuvation Bio 2.55Moderate Buy$12.50123.93% UpsideCurrent Analyst Ratings BreakdownLatest CCCC, GLUE, NUVB, and ATAI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/6/2026ATAIAtai Beckley Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.006/30/2026GLUEMonte Rosa Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$30.00 ➝ $35.006/30/2026GLUEMonte Rosa Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$30.00 ➝ $35.006/24/2026ATAIAtai Beckley Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/10/2026NUVBNuvation Bio CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform6/8/2026ATAIAtai Beckley HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.005/26/2026ATAIAtai Beckley AegisSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/26/2026NUVBNuvation Bio Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/11/2026GLUEMonte Rosa Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Sell (D)5/11/2026GLUEMonte Rosa Therapeutics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$30.00 ➝ $31.005/5/2026NUVBNuvation Bio Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$20.00(Data available from 7/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATAIAtai Beckley$4.09M446.48N/AN/A$0.69 per share7.19CCCCC4 Therapeutics$35.95M12.73N/AN/A$2.65 per share1.56GLUEMonte Rosa Therapeutics$123.67M15.88N/AN/A$3.58 per share6.49NUVBNuvation Bio$62.90M30.90N/AN/A$0.88 per share6.34Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATAIAtai Beckley-$660.05M-$2.23N/AN/AN/A-19,019.44%-89.79%-63.58%8/13/2026 (Estimated)CCCCC4 Therapeutics-$104.99M-$1.19N/AN/AN/A-297.76%-50.68%-33.22%8/6/2026 (Estimated)GLUEMonte Rosa Therapeutics-$38.63M-$1.48N/AN/AN/A-302.69%-40.99%-25.94%8/6/2026 (Estimated)NUVBNuvation Bio-$204.63M-$0.43N/AN/AN/A-102.06%-44.10%-23.80%8/6/2026 (Estimated)Latest CCCC, GLUE, NUVB, and ATAI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q4 2025ATAIAtai Beckley-$0.11-$0.08+$0.03-$0.08$0.22 million$0.95 million5/12/2026Q1 2026CCCCC4 Therapeutics-$0.2506-$0.20+$0.0506-$0.20$4.42 million$6.15 million5/7/2026Q1 2026GLUEMonte Rosa Therapeutics-$0.3882-$0.45-$0.0618-$0.45$10.95 million$4.21 million5/4/2026Q1 2026NUVBNuvation Bio-$0.0280$0.01+$0.0380$0.01$66.22 million$83.23 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthATAIAtai BeckleyN/AN/AN/AN/AN/ACCCCC4 TherapeuticsN/AN/AN/AN/AN/AGLUEMonte Rosa TherapeuticsN/AN/AN/AN/AN/ANUVBNuvation BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATAIAtai BeckleyN/AN/AN/ACCCCC4 TherapeuticsN/A9.009.00GLUEMonte Rosa TherapeuticsN/A9.549.54NUVBNuvation Bio0.157.447.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATAIAtai Beckley28.41%CCCCC4 Therapeutics78.81%GLUEMonte Rosa Therapeutics79.96%NUVBNuvation Bio61.67%Insider OwnershipCompanyInsider OwnershipATAIAtai Beckley26.80%CCCCC4 Therapeutics5.60%GLUEMonte Rosa Therapeutics6.40%NUVBNuvation Bio30.11%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATAIAtai Beckley80368.17 million269.50 millionOptionableCCCCC4 Therapeutics150110.57 million104.38 millionOptionableGLUEMonte Rosa Therapeutics9084.48 million79.07 millionOptionableNUVBNuvation Bio60348.20 million243.36 millionOptionableCCCC, GLUE, NUVB, and ATAI HeadlinesRecent News About These CompaniesNuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes OfferingJuly 6 at 5:09 PM | prnewswire.comIs Nuvation Bio’s (NUVB) Expanding Taletrectinib Footprint Quietly Rewriting Its Global Oncology Narrative?July 2, 2026 | finance.yahoo.comNuvation Bio Issues Convertible Notes, Retires Secured DebtJune 30, 2026 | tipranks.comNuvation Bio Stock Is Up 190% Despite Recent Pressure. Should Investors Care About This $753,000 Insider Sale?June 29, 2026 | fool.comNuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United KingdomJune 29, 2026 | prnewswire.comKerry Wentworth Sells 63,000 Shares of Nuvation Bio (NYSE:NUVB) StockJune 26, 2026 | americanbankingnews.comStacy Markel Sells 125,000 Shares of Nuvation Bio (NYSE:NUVB) StockJune 26, 2026 | americanbankingnews.comNuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior NotesJune 25, 2026 | prnewswire.comWhy is NUVB stock falling today?June 25, 2026 | msn.comNuvation Bio Announces Proposed Convertible Senior Notes OfferingJune 25, 2026 | prnewswire.comNuvation Bio (NYSE:NUVB) CFO Philippe Sauvage Sells 47,668 Shares of StockJune 25, 2026 | insidertrades.comWhy Nuvation Bio (NYSE:NUVB) Is Becoming A Small-Cap Stock To Watch?June 23, 2026 | kalkinemedia.comKNuvation Bio Inc. (NYSE:NUVB) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJune 22, 2026 | marketbeat.comNuvation Bio (NYSE:NUVB) Leads Biotech Penny WatchJune 19, 2026 | kalkinemedia.comKIshara Investments LP Buys New Shares in Nuvation Bio Inc. $NUVBJune 18, 2026 | marketbeat.comACT Capital Management LLC Makes New $5.47 Million Investment in Nuvation Bio Inc. $NUVBJune 18, 2026 | marketbeat.comNuvation Bio Inc. $NUVB Stock Holdings Lowered by Omega Fund Management LLCJune 17, 2026 | marketbeat.comWhy Nuvation Bio Is Turning Heads As A Biotech Penny Stock?June 17, 2026 | kalkinemedia.comKHere’s What the Acquisition of Nuvalent Means for Nuvation Bio (NUVB)June 17, 2026 | finance.yahoo.comWhy Is Nuvation Bio Back On Penny Stock Watchlists?June 16, 2026 | kalkinemedia.comKNuvation Bio: David Hung's Latest Venture Looks Undervalued At Current LevelJune 15, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCCCC, GLUE, NUVB, and ATAI Company DescriptionsAtai Beckley NASDAQ:ATAI$4.96 -0.23 (-4.43%) Closing price 07/6/2026 04:00 PM EasternExtended Trading$5.16 +0.20 (+4.03%) As of 07:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Atai Beckley N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. Atai Beckley N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.C4 Therapeutics NASDAQ:CCCC$4.14 -0.16 (-3.72%) Closing price 07/6/2026 04:00 PM EasternExtended Trading$4.18 +0.04 (+0.97%) As of 07:46 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Monte Rosa Therapeutics NASDAQ:GLUE$23.25 -0.96 (-3.97%) Closing price 07/6/2026 04:00 PM EasternExtended Trading$23.25 0.00 (0.00%) As of 07:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.Nuvation Bio NYSE:NUVB$5.58 -0.12 (-2.07%) Closing price 07/6/2026 03:59 PM EasternExtended Trading$5.70 +0.12 (+2.11%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Flash Crash or Cash? The AI Hardware Reset Investors Can’t Ignore KBR Insiders Are Buying While the Market Misreads Its Spinoff Doug Casey Calls AI a Super Bubble, Bets on Energy, Gold Miners and Grains Contrarian Alert: 5 Downgraded Stocks That May Reward Long-Term Investors This Edge AI Stock Just Got a Huge Vote of Confidence From Wall Street AI Is Selling Off, But These 5 Stocks Could Benefit Next MarketBeat Week in Review – 06/29 - 07/03 Analysts Just Raised Price Targets On These 3 Semiconductor Equipment Stocks Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
